Cobus Loots, CEO of Pan African Resources, on delivering sector-leading returns for shareholders. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDDDD.L Share News (DDDD)

  • There is currently no data for DDDD

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

FTSE 250 movers: Miners drag index down, Synthomer spikes higher

Tue, 11th Aug 2015 14:15

(ShareCast News) - The FTSE 250 index was by late on Tuesday afternoon giving up some of the gains made late the day before, as commodities-focused stocks were hit by China's devaluation and corporate news received mixed reviews.By 1540 BST the index was down 0.47% at 17,677.29 points, with Vedanta Resources losing most of the ground that it had gained on Monday.Other mid-cap basic resources hit as the dollar appreciated 1.8% against China's yuan included copper producer Kaz Minerals, Premier Oil and platinum miner Lonmin.Although its shares gained initially, Just Retirement was firmly in the red later in the day after agreeing a 60-40 merger in its favour with annuities rival Partnership Assurance to create a new £1.7bn company.Woodford Patient Capital Trust, one of the funds run by star fund manager Neil Woodford, was lower despite after publishing first half-year results since listing in April this year, with the shares trading at an 11% premium to net assets value per share. But the shares were hit by the announcement of a tap issuance programme to satisfy excess demand in the secondary market, but the new shares issued will be done so at a premium to NAV and should therefore be accretive to existing shareholders.Building materials group SIG fell despite posting a rise in first-half pre-tax profit and raising its interim dividend. The company said its margins were under pressure, with variable trading conditions in Europe and a significant weakening of the euro which hit revenues.Leading the 250 risers on Tuesday was Synthomer, as the latex maker reported a first-half profit before tax of £51.4m, up 14% from the first half of last year. The company said the performance was strong given significant exchange rate headwinds, and warned its full year result could suffer if conditions continued.Online and catalogue retailer N Brown was lifted despite the release of mixed UK retail sales data from the BRC. Online non-food sales rose by 14.7%, higher than expected, but ladieswear had a disappointing month, though accessories, kidswear and summer footwear enjoyed strong sales.Allied Minds, after being revealed as one of the stocks in the Woodford Patient Capital Trust's top ten holdings, was another big gainer. (4d Pharma and Vernalis, an AIM company, also gained strongly later in the session, though Imperial Innovations was a faller, disproving any Woodford-based stock picking strategies.)FTSE 250 - RisersSynthomer (SYNT) 350.80p +6.40%Allied Minds (ALM) 471.50p +5.88%Zoopla Property Group (WI) (ZPLA) 257.90p +5.65%Nostrum Oil & Gas (NOG) 570.00p +3.92%Euromoney Institutional Investor (ERM) 1,115.00p +3.82%Cineworld Group (CINE) 550.00p +3.38%Centamin (DI) (CEY) 55.05p +2.42%Evraz (EVR) 97.75p +2.20%Brown (N.) Group (BWNG) 322.00p +2.09%Acacia Mining (ACA) 241.20p +1.99%FTSE 250 - FallersVedanta Resources (VED) 468.00p -4.76%Shawbrook Group (SHAW) 324.60p -4.36%Kaz Minerals (KAZ) 156.70p -3.81% Just Retirement Group (JRG) 191.20p -3.77%Woodford Patient Capital Trust (WPCT) 115.50p -3.19%Premier Oil (PMO) 119.50p -3.00%Lonmin (LMI) 43.05p -2.93%SIG (SHI) 196.10p -2.58%Brewin Dolphin Holdings (BRW) 301.00p -2.40%Ocado Group (OCDO) 374.30p -2.32%
More News
13 Jul 2020 14:39

4D Pharma To Raise GBP7.7 Million In Share Issue, Eyes US Listing

4D Pharma To Raise GBP7.7 Million In Share Issue, Eyes US Listing

Read more
6 Jul 2020 12:38

Next part of tumour trial begins for 4D Pharma

(Sharecast News) - Biotherapeutics developer 4D Pharma has begin the treatment of the first patients in part B of its phase 1 and 2 clinical trial of 'MRx0518' in combination with immune checkpoint inhibitor 'Keytruda', or pembrolizumab, it announced on Monday, in patients with acquired resistance to prior immune checkpoint therapy.

Read more
6 Jul 2020 10:17

4D Pharma Starts Treatment Of Patients In Phase 2 Of MRx0518 Trial

4D Pharma Starts Treatment Of Patients In Phase 2 Of MRx0518 Trial

Read more
2 Jul 2020 12:14

Patient enrolment begins for 4D's Covid therapy candidate

(Sharecast News) - Biotherapeutics-focussed pharmaceutical company 4D Pharma announced on Thursday that its phase 2 clinical trial of the oral immunomodulator 'MRx-4DP0004', for patients hospitalised with Covid-19, was now open to enrolment, with dosing of the first patients expected shortly.

Read more
2 Jul 2020 09:16

4d Pharma Starts Covid-19 Patients Enrollment For MRx-4DP0004 Study

4d Pharma Starts Covid-19 Patients Enrollment For MRx-4DP0004 Study

Read more
26 May 2020 10:06

4d Pharma Reports Revenue For 2019 But Loss Widens On Higher Costs

4d Pharma Reports Revenue For 2019 But Loss Widens On Higher Costs

Read more
11 May 2020 10:45

4D Pharma Completes First Part Of Clinical Trial For Cancer Treatment

4D Pharma Completes First Part Of Clinical Trial For Cancer Treatment

Read more
20 Apr 2020 11:08

4D Pharma receives expedited approval for coronavirus study

(Sharecast News) - Pharmaceutical company 4D Pharma received expedited acceptance from the UK Medicines and Healthcare Products Regulatory Agency on Monday to kick off a Phase II study of MRx-4DP0004 in patients with Covid-19.

Read more
20 Apr 2020 10:30

4D Pharma Stock Jumps 60% As Gets Approval For Study Of Covid-19 Drug

4D Pharma Stock Jumps 60% As Gets Approval For Study Of Covid-19 Drug

Read more
17 Apr 2020 13:53

4D Pharma upbeat on key findings from Blautix study

(Sharecast News) - Biotherapeutics-focussed pharmaceutical company 4D Pharma announced key findings of a planned interim analysis in its 'BHT-II-0002' study in irritable bowel syndrome (IBS) on Friday.

Read more
17 Apr 2020 10:14

4D Pharma Appoints New Chair, Reports Encouraging Blautix Trial Data

4D Pharma Appoints New Chair, Reports Encouraging Blautix Trial Data

Read more
18 Mar 2020 18:09

DIRECTOR DEALINGS SUMMARY: Wizz Air Chair Buys GBP700,000 In Shares

DIRECTOR DEALINGS SUMMARY: Wizz Air Chair Buys GBP700,000 In Shares

Read more
18 Feb 2020 18:44

UPDATE:4d Pharma Raises GBP22 Million Through Placing And Subscription

UPDATE:4d Pharma Raises GBP22 Million Through Placing And Subscription

Read more
18 Feb 2020 09:26

4D Pharma raising at least ?18m via placing and subscription

(Sharecast News) - Live biotherapeutic pharmaceutical company 4D Pharma announced a proposed fundraising on Tuesday, by way of a placing and subscription of new ordinary shares and warrants, to raise gross proceeds of at least ?18m via an accelerated bookbuild process.

Read more
18 Feb 2020 09:03

4d Pharma Plans GBP18 Million Fundraise To Fund Clinical Studies

4d Pharma Plans GBP18 Million Fundraise To Fund Clinical Studies

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.